This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kort, E. J. Articles by Teh, B. T. Search for Related Content PubMed PubMed Citation Articles by Kort, E. J. Articles by Teh, B. T.

The E2F3-Oncomir-1 Axis Is Activated in Wilms' Tumor

Laboratories of ¹ Molecular Epidemiology, ² Cancer Genetics, and ³ Computational Biology, Van Andel Research Institute; ⁴ Division of Pediatric Hematology/Oncology, De Vos Children's Hospital, Grand Rapids, Michigan; ⁵ Department of Pathology, University of Chicago; ⁶ Department of Pathology, Northwestern University, Chicago, Illinois; and ⁷ NCCS-VARI Translational Research Laboratory, National Cancer Centre, Singapore

Requests for reprints: Bin Tean Teh, Laboratory of Cancer Genetics, Van Andel Research Institute, 333 Bostwick Avenue Northeast, Grand Rapids, MI 49503. Phone: 616-234-5296; Fax: 616-234-5297; E-mail: Bin.Teh{at}vai.org or Eric J. Kort, Laboratory of Cancer Genetics, Van Andel Research Institute, 333 Bostwick Avenue Northeast, Grand Rapids, MI 49503. Phone: 616-234-5552; Fax: 616-234-5553; E-mail: eric.kort{at}vai.org.

Key Words: Pediatric cancers • Gene expression profiling • Cancer genome anatomy: comparative expression patterns • Oncogenic transcription factors: leukemias/lymphomas/solid tumors

Oncomir-1 is an oncogenic cluster of microRNAs (miRNA) located on chromosome 13. Previous in vitro studies showed that it is transcriptionally regulated by the transcription factor E2F3. In this report, we combine expression profiling of both mRNA and miRNAs in Wilms' tumor (WT) samples to provide the first evidence that the E2F3-Oncomir-1 axis, previously identified in cell culture, is deregulated in primary human tumors. Analysis of RNA expression signatures showed that an E2F3 gene signature was activated in all WT samples analyzed, in contrast to other kidney tumors. This finding was validated by immunohistochemistry on the protein level. Expression of E2F3 was lowest in early-stage tumors and highest in metastatic tissue. Expression profiling of miRNAs in WT showed that expression of each measured member of the Oncomir-1 family was highest in WT relative to other kidney tumor subtypes. Quantitative PCR confirmed that these miRNAs were overexpressed in WT relative to normal kidney tissue. These results suggest that the E2F3-Oncomir-1 axis is activated in WT. Our study also shows the utility of integrated genomics combining gene signature analysis with miRNA expression profiling to identify protein-miRNA interactions that are perturbed in disease states. [Cancer Res 2008;68(11):4034–8]

This article has been cited by other articles:

				M. Inomata, H. Tagawa, Y.-M. Guo, Y. Kameoka, N. Takahashi, and K. Sawada MicroRNA-17-92 down-regulates expression of distinct targets in different B-cell lymphoma subtypes Blood, January 8, 2009; 113(2): 396 - 402. [Abstract] [Full Text] [PDF]